Quality of Life.

The reality is staggering. One in four dogs will develop cancer in their lifetime. Cancer is the leading cause of death in dogs over the age of two. It’s often discovered in late stages of the disease when treatment is difficult. Families of these pets are urgently looking for new and better options that not only prolong their companion’s life, but also improve quality of life. ELIAS Animal Health is elevating the hope of veterinarians and pet owners alike by changing the way cancer is fundamentally treated.

Cancer Immunotherapy. Personalized

Our approach is profoundly simple: Every canine patient is unique. Every cancer is unique. To ultimately win against this devastating killer, cancer therapy itself must also be unique. ELIAS Cancer Immunotherapy (ECI®), our Autologous Prescription Product, harnesses the power of the dog’s own immune system to eliminate the cancer.

Killer T cells. Activated.

The complexity of cancer itself makes the development and delivery of effective treatments a steep challenge. Research has shown that ex vivo activated T cells have the capability to effectively kill cancer cells, including cancer stem cells. ELIAS cancer immunotherapy utilizes adoptive cell therapy to deliver an army of activated T cells.

Two Methods. Combined.

ELIAS Animal Health has developed a unique treatment protocol that vaccinates the dog with its own cancer cells to produce an immune response. Personalized T cells are then safely obtained from the patient through apheresis and activated to produce a large population of killer T cells that are reinfused into the patient to kill the cancer.

Benefits. Expanded.

ELIAS’ cancer immunotherapy is a platform technology that has demonstrated effectiveness in multiple rodent and human cancers, while avoiding or minimizing the need for chemotherapy or radiation treatment. ELIAS is taking cancer treatment to new heights.

Clinical trials. Initiated.

ELIAS Animal Health has completed their osteosarcoma clinical trial and is anticipating the results which will be released in October. B cell lymphoma results will be available by year end. To meet the demand for safer and more effective treatments for other canine cancers, ELIAS Animal Health is planning on additional clinical trials of its Autologus Prescription Product Platform in the future. Please monitor this site for information on other trials.




*Product is an experimental autologous prescription product available for sale to veterinarians under 9 CFR 103.3

If you would like additional information on ELIAS Animal Health, please complete and submit the form below: